Evidence map›Paper›PMID 38882557›Full record

ArticleCase reports in urology2024

Bladder Cancer Invading the Prostate and Penis and Multiple Bone Metastases Showing Significant Improvement after a Short-Term Pembrolizumab Therapy following Radiation and Gemcitabine and Cisplatin Therapy Leading to a Pathologically Complete Remission.

Kyohei Ishida, Akira Ogose, Gen Kawaguchi, Go Hasegawa, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama

Abstract readCase Reports
In one paragraph

Article in Case reports in urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kyohei IshidaDepartment of Urology Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Akira OgoseDepartment of Orthopedic Surgery Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Gen KawaguchiDepartment of Radiotherapy Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Go HasegawaDepartment of Pathology Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Yohei IkedaDepartment of Diagnostic Radiology Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Noboru HaraDepartment of Urology Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.
Tsutomu NishiyamaDepartment of Urology Uonuma Institute of Community Medicine Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan.ORCID https://orcid.org/0000-0002-5684-8364

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 65-year-old man was diagnosed with bladder cancer invading the prostate and penis and multiple bone metastases. He underwent palliative radiation (30 Gy/10 fr) through vertebral bones (Th3 and Th12-L5) and pelvic bones for pain control. The patient received pembrolizumab therapy after three courses of gemcitabine and cisplatin therapy. CT four weeks after starting pembrolizumab therapy showed that both the primary and metastatic lesions had notably reduced in size, and no new lesion was detected. He subsequently fell, resulting in a femoral neck pathological fracture, and underwent hemiarthroplasty. Pathological examination of the pathological fracture site revealed no residual tumor tissue.

Identifiers

PMID38882557
PMCPMC11178393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.